(Press-News.org) Phoenix, AZ (May 19, 2023)- Results from the Evolut FX TAVR (Transcatheter Aortic Valve Replacement) Clinical Survey were presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2023 Scientific Sessions. The survey, comprised of feedback from physicians across the United States, reported improved deliverability, tracking, and deployment of the next-generation device compared to its predecessor.
Aortic stenosis (AS), is one of the most common valvular heart diseases and can potentially lead to heart failure. Once symptoms of AS begin, average patient survival can be as short as two years without treatment1. TAVR is a minimally invasive procedure to treat patients with symptomatic severe AS that has been shown to improve patient survival.
Physician feedback on the next-generation Evolut FX TAVR system (Medtronic) was obtained from June 24-September 11, 2022, at 69 U.S. centers from 539 physician administered surveys (or from 539 Evolut FX implants) with a broad range of implant experience and volume. Survey results compared Evolut FX to physicians earlier experiences with Evolut PRO+ system using descriptive statistics.
“Commissural alignment during TAVR procedures is key to improving coronary access, blood flow and valve performance,” said Tanvir Bajwa, MD, FACC, FSCAI and interventional cardiologist and medical director of the Structural Heart Program at Aurora St. Luke’s Medical Center and Aurora Medical Center-Oshkosh, in Milwaukee, Wis., and lead author of the analysis, “These real-world physician insights underscore the procedural benefits of improved deliverability with a more predictable deployment.”
Evolut FX valves (23 mm, 7%; 26 mm, 30%; 29 mm, 45%; 34 mm, 19%) were implanted via transfemoral (TF) access in 97% of cases. The cusp-overlap technique (COT) was used in 89% (457/516) of cases. Commissural alignment was achieved in 96% (447/465) of TF cases using the cusp overlap view. During initial deployment, no noticeable ventricular movement of the Evolut FX device was reported in 79% (398/506) of cases and 79% (413/526) of operators rated the FX as having a more predictable deployment.
The authors note they intend to study how the device enhancements impact patient outcomes in future clinical trials.
Session Details:
“Performance and Use of the Evolut FX Transcatheter Aortic Valve System: Updated Results from the Evolut FX Limited Market Release Clinical Survey” [Friday, May 19, 2023, 3:40-5:10 PM MST, West 103, First Floor, Phoenix Convention Center]
About SCAI:
The Society for Cardiovascular Angiography & Interventions (SCAI) is a non-profit professional association with over 4,500 members representing interventional cardiologists and cardiac catheterization teams in the United States. SCAI promotes excellence in interventional cardiovascular medicine for both adults and children through education, representation, and the advancement of quality standards to enhance patient care.
For more information about the SCAI 2023 Scientific Sessions, visit https://scai.org/scai-2023-scientific-sessions. Follow @SCAI on Twitter for the latest heart health news and use #SCAI2023 to follow the latest discussions.
###
[1] Ross J Jr, Braunwald E. Aortic stenosis. Circulation. July 1968; 38(1 Suppl):61-67.
END
Phoenix, AZ (May 19, 2023)- A new study examining the criteria proposed by the European Society of Cardiology (ESC) to prescribe long-term treatment with more than one blood thinner after percutaneous coronary intervention was presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2023 Scientific Sessions. The study confirmed that patients presenting the characteristics proposed in the ESC guidelines are more likely to experience complications due to blood clotting in the coronary arteries. These patients may therefore benefit from a long-term treatment with more ...
Methane, a greenhouse gas known to do about 80 times more damage to the atmosphere than carbon dioxide over a 20-year period, is often overlooked by policymakers and governments. In a review publishing in the journal One Earth on May 19, researchers analyzed the coverage, stringency, and real-world impact of current global methane emissions policies for the first time. They found that only 13% of emissions are currently covered by direct mitigation policies.
In order to limit climate warming to 1.5 degrees Celsius in accordance with the Paris Agreement, global methane emissions need to be cut by at least 40%–45%, according to the 2021 Global Methane Assessment—a feat that the ...
New research from Queen Mary University of London shows that only around 13% of global methane emissions are regulated, despite methane emissions causing at least 25% of current global warming.
The global review, published on 19 May in One Earth, also found that little is known about the effectiveness of the policies that exist, with potentially unrepresentative methane emission estimations used rather than actual measurements. Inaccurate estimations can also mean the issue is taken less seriously by decision-makers by masking its severity.
The researchers argue that the lack ...
(Philadelphia, PA) – Genetic alterations that give rise to a rare, fatal disorder known as MOGS-CDG paradoxically also protect cells against infection by viruses. Now, scientists at the Lewis Katz School of Medicine at Temple University have harnessed this unusual protective ability in a novel gene-editing strategy aimed at eliminating HIV-1 infection with no adverse effects on cell mortality.
The new approach, described online April 28 in the journal Molecular Therapy – Nucleic Acids, is based on a combination of two gene-editing constructs, one that ...
About The Study: This survey study found that although there has been substantial policy attention around incentivizing COVID-19 vaccination, fewer than 1 in 10 vaccinated individuals in a nationally representative sample of U.S. adults reported receiving an incentive. Most vaccinated respondents reported that an incentive did not make a difference in their decision-making to get the COVID-19 vaccine.
Authors: Laura J. Faherty, M.D., M.P.H., M.S.H.P., of the RAND Corporation in Boston, is the corresponding author.
To access the ...
About The Study: In this decision analytical model, increased uptake of bivalent booster vaccination among eligible age groups was associated with decreased hospitalizations and school absenteeism in the pediatric population. These findings suggest that although COVID-19 prevention strategies often focus on older populations, the benefits of booster campaigns for children may be substantial.
Authors: Alison P. Galvani, Ph.D., of the Yale School of Public Health in New Haven, Connecticut, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this ...
About The Study: In this case-control surveillance study of more than 100,000 pregnancies, COVID-19 booster vaccination in pregnancy was not associated with spontaneous abortion. These findings support the safety of recommendations for COVID-19 booster vaccination, including in pregnant populations.
Authors: Elyse O. Kharbanda, M.D., M.P.H., of HealthPartners Institute in Minneapolis, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2023.14350)
Editor’s ...
HealthPartners Institute researchers have published new data in JAMA Network Open that shows monovalent COVID-19 booster vaccinations administered in early pregnancy (before 20 weeks’ gestation) were not associated with miscarriage. The research adds to the growing understanding about the safety of COVID-19 booster vaccinations among people who are pregnant.
The researchers analyzed data from more than 100,000 pregnancies between six and 19 weeks’ gestation from eight large health systems participating in the Vaccine Safety Datalink (VSD). The data was collected between Nov. ...
Biophysicists have designed a new cell-like transport system that represents an important milestone on the road to artificial cells.
Creating artificial cells with life-like characteristics out of a minimal set of components is a major goal of synthetic biology. Autonomous motion is a key capability here, and one that is difficult to reproduce in the test tube. A team led by physicist Erwin Frey, Professor of Statistical and Biological Physics at LMU, and Petra Schwille from the Max Planck Institute of Biochemistry, has now made ...
Every year, more than 40,000 women die of ovarian cancer in Europe. Ovarian cancer is a genetically very heterogeneous disease, which makes it exceptionally difficult to study and treat. The prognosis is particularly poor in ovarian high grade serous carcinoma (HGSC), a subtype of ovarian cancer. Less than 40% of patients with this subtype survive five years after their diagnosis.
The researchers were able to classify HGSC tumours into three groups on the basis of genomic changes. The groups differ in the intracellular signalling pathways, the ways in which the tumours grow, and response ...
